Tuberculosis and Biologic Therapies Anti-Tumor Necrosis Factor-α and Beyond

被引：51

作者：

Godfrey, Mark S. ^{[1
]}

Friedman, Lloyd N. ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, 300 Cedar St,TAC S425,POB 208057, New Haven, CT 06520 USA

来源：

CLINICS IN CHEST MEDICINE | 2019年 / 40卷 / 04期

关键词：

Tuberculosis; Biological therapy; Tumor necrosis factor-alpha; Antibodies; Monoclonal; Opportunistic infection; GAMMA RELEASE ASSAYS; ANTI-TNF THERAPY; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; LONG-TERM; POSTMARKETING SURVEILLANCE; ANKYLOSING-SPONDYLITIS; IMMUNE RECONSTITUTION;

D O I：

10.1016/j.ccm.2019.07.003

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Biologic drugs have revolutionized the treatment of certain hematologic, autoimmune, and malignant diseases, but they may place patients at risk for reactivation or acquisition of tuberculosis. This risk is highest with the tumor necrosis factor-alpha (TNF-alpha) inhibitors. Amongst this class of drugs, the monoclonal antibodies (infliximab, adalimumab, golimumab) and antibody fragment (certolizumab) carry an increased risk compared to the soluble receptor fusion molecule, etanercept. Treatment of latent TB is critical to decrease the risk of reactivation. Data continues to emerge regarding tuberculosis risk associated with novel biologics targeting cytokines involved in tuberculosis control.

引用

页码：721 / +

页数：20

共 152 条

[1]

Abreu C, 2013, J CROHNS COLITIS, V7, P175, DOI [10.1016/j.crohns.2012.04.018, 10.1016/j.crohns.2013.03.004]

[2] Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study [J].

Abubakar, Ibrahim ;

Drobniewski, Francis ;

Southern, Jo ;

Sitch, Alice J. ;

Jackson, Charlotte ;

Lipman, Marc ;

Deeks, Jonathan J. ;

Griffiths, Chris ;

Bothamley, Graham ;

Lynn, William ;

Burgess, Helen ;

Mann, Bobby ;

Imran, Ambreen ;

Sridhar, Saranya ;

Tsou, Chuen-Yan ;

Nikolayevskyy, Vladyslav ;

Rees-Roberts, Melanie ;

Whitworth, Hilary ;

Kon, Onn Min ;

Haldar, Pranab ;

Kunst, Heinke ;

Anderson, Sarah ;

Hayward, Andrew ;

Watson, John M. ;

Milburn, Heather ;

Lalvani, Ajit .

LANCET INFECTIOUS DISEASES, 2018, 18 (10) :1077-1087

[3]

[Anonymous], 2000, MMWR Recomm Rep, V49, P1

[4] The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies [J].

Ai, Jing-Wen ;

Zhang, Shu ;

Ruan, Qiao-Ling ;

Yu, Yi-Qi ;

Zhang, Bing-Yan ;

Liu, Qi-Hui ;

Zhang, Wen-Hong .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (12) :2229-2237

[5]

Alkadi Amjad, 2017, Int J Health Sci (Qassim), V11, P41

[6] Role Played by the Programmed Death-1-Programmed Death Ligand Pathway during Innate Immunity against Mycobacterium tuberculosis [J].

Alvarez, Ivana B. ;

Pasquinelli, Virginia ;

Jurado, Javier O. ;

Abbate, Eduardo ;

Musella, Rosa M. ;

de la Barrera, Silvia S. ;

Garcia, Veronica E. .

JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (04) :524-532

[7]

[Anonymous], GLOB TUB REP 2018

[8]

[Anonymous], 2018, REMICADE

[9]

[Anonymous], 2005, THORAX, DOI DOI 10.1136/thx.2005.046797

[10] A patient with de novo tuberculosis during anti-tumor necrosis factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment [J].

Arend, Sandra M. ;

Leyten, Eliane M. S. ;

Franken, Willeke P. J. ;

Huisman, Erik M. ;

van Dissel, Jaap T. .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (11) :1470-1475

← 1 2 3 4 5 6 7 8 9 10 →